Preprint: Please note that this article has not completed peer review.
Research article

The association of change in serum cholesterol levels and clinical treatment response in patients with schizophrenia: a prospective, randomized and open-label study

Yi-Lung Chen, Chih-Chiang Chiu, Kun-Po Chen, Ming-Hong Tai, For-Wey Lung

Abstract

Background: In the past, it was suggested that dyslipidemia was associated with clinical improvement in patients with schizophrenia treated with antipsychotics; however, measurement at a single time point post-treatment, as done in most studies, could have contributed to the inconsistent results. The aim of this study was to investigate whether changes in serum levels of lipid and other covariates were associated with clinical response in patients with schizophrenia treated with atypical antipsychotics, using repeated measurements and considering time effects.

Method: A total of 90 patients with schizophrenia were enrolled in this 12-week prospective, randomized and open label study. Positive and Negative Syndrome Scale (PANSS) score and a standard serum lipid profile were measured at baseline (day 0) and subsequently followed up at weeks 4, 8 and 12. The generalized estimating equation (GEE) model was applied to examine the relationship between serum lipids and treatment response, controlling for other potential variables.

Results: The results of GEE analysis showed that the increase in serum total cholesterol levels during 12 weeks’ antipsychotic treatment was significantly associated with a reduction in PANSS total score (β = −0.37, p = 0.02) and positive symptom score (β = −0.34, p = 0.01) over time.

Conclusions: These findings revealed that the change in serum total cholesterol level was positively associated with the therapeutic efficacy of atypical antipsychotics. Serum total cholesterol may be a potential predictor of clinical response in patients with schizophrenia treated with atypical antipsychotics.

Trial Registration: ClinicalTrials.gov identifier: NCT03730857. The trial was retrospectively registered on 11 Feb, 2019.

Keywords
Paliperidone; Risperidone; Olanzapine; Lipid levels; Schizophrenia

Figures

Introduction

Methods

Results

Discussion

Conclusion

Supporting information

Abbreviations

Declarations

References

Tables

Supplementary Files

STATUS: In Review

Comments: 0
PDF Downloads: 0
HTML Views: 8

Integrity Check:

Peer Review Timeline

Version 1

Posted 13 Aug, 2019

  • No community comments so far
  • Editorial decision: Reject after review

    On 13 Aug, 2019

  • Review #3 received

    Received 12 Aug, 2019

  • Reviewer #3 agreed

    On 11 Aug, 2019

  • Review #2 received

    Received 09 Aug, 2019

  • Review #1 received

    Received 09 Aug, 2019

  • Reviewer #2 agreed

    On 08 Aug, 2019

  • 4 reviewer(s) invited

    Invitations sent on 08 Aug, 2019

  • Reviewer #1 agreed

    On 08 Aug, 2019

  • Editor assigned

    On 07 Aug, 2019

  • Submission checks complete

    On 06 Aug, 2019

  • Editor invited

    On 06 Aug, 2019

Subject Areas

Psychiatry

More from BMC Psychiatry

Comments (0)

Comments can take the form of short reviews, notes or questions to the author. Comments will be posted immediately, but removed and moderated if flagged.

Learn more about our company.

Preprint: Please note that this article has not completed peer review.
Research article

The association of change in serum cholesterol levels and clinical treatment response in patients with schizophrenia: a prospective, randomized and open-label study

Yi-Lung Chen, Chih-Chiang Chiu, Kun-Po Chen, Ming-Hong Tai, For-Wey Lung

STATUS: In Review

Comments: 0
PDF Downloads: 0
HTML Views: 8

Integrity Check:

  • Article

  • Peer Review Timeline

  • Related Articles

  • Comments

Abstract

Background: In the past, it was suggested that dyslipidemia was associated with clinical improvement in patients with schizophrenia treated with antipsychotics; however, measurement at a single time point post-treatment, as done in most studies, could have contributed to the inconsistent results. The aim of this study was to investigate whether changes in serum levels of lipid and other covariates were associated with clinical response in patients with schizophrenia treated with atypical antipsychotics, using repeated measurements and considering time effects.

Method: A total of 90 patients with schizophrenia were enrolled in this 12-week prospective, randomized and open label study. Positive and Negative Syndrome Scale (PANSS) score and a standard serum lipid profile were measured at baseline (day 0) and subsequently followed up at weeks 4, 8 and 12. The generalized estimating equation (GEE) model was applied to examine the relationship between serum lipids and treatment response, controlling for other potential variables.

Results: The results of GEE analysis showed that the increase in serum total cholesterol levels during 12 weeks’ antipsychotic treatment was significantly associated with a reduction in PANSS total score (β = −0.37, p = 0.02) and positive symptom score (β = −0.34, p = 0.01) over time.

Conclusions: These findings revealed that the change in serum total cholesterol level was positively associated with the therapeutic efficacy of atypical antipsychotics. Serum total cholesterol may be a potential predictor of clinical response in patients with schizophrenia treated with atypical antipsychotics.

Trial Registration: ClinicalTrials.gov identifier: NCT03730857. The trial was retrospectively registered on 11 Feb, 2019.

Figures

Introduction

Methods

Results

Discussion

Conclusion

Supporting information

Abbreviations

Declarations

References

Tables

Learn more about our company.